Lachlan Hanbury Brown

Stock Analyst at William Blair

(0.92)
# 2,520
Out of 4,974 analysts
138
Total ratings
44.4%
Success rate
-1.9%
Average return

Stocks Rated by Lachlan Hanbury Brown

Ocular Therapeutix
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $10.19
Upside: -
Surrozen
Sep 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $17.77
Upside: -
Eupraxia Pharmaceuticals Inc.
Aug 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.20
Upside: -
Harrow
Aug 20, 2026
Reiterated: Buy
Price Target: n/a
Current: $33.84
Upside: -
ARS Pharmaceuticals
Aug 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.25
Upside: -
LENZ Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.23
Upside: -
Tarsus Pharmaceuticals
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $78.23
Upside: -
Kalaris Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.20
Upside: -
Viridian Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $21.83
Upside: -
Solid Biosciences
Mar 20, 2026
Reiterated: Buy
Price Target: n/a
Current: $8.37
Upside: -
Reiterated: Buy
Price Target: n/a
Current: $11.65
Upside: -